CorMedix (CRMD) – Investment Analysts’ Recent Ratings Changes

CorMedix (NASDAQ: CRMD) has recently received a number of price target changes and ratings updates:

• 4/28/2026 – CorMedix had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $14.00 price target on the stock, up from $13.00.
• 4/28/2026 – CorMedix had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $19.00 price target on the stock.
• 4/28/2026 – CorMedix had its price target raised by Leerink Partners from $13.00 to $14.00. They now have an “outperform” rating on the stock.
• 4/27/2026 – CorMedix had its price target raised by Needham & Company LLC from $14.00 to $15.00. They now have a “buy” rating on the stock.
• 4/27/2026 – CorMedix had its “buy” rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.